Indivior (NASDAQ:INDV) Sets New 12-Month High - Here's What Happened

Key Points

• Indivior PLC shares reached a new 52-week high of $25.00 during trading, indicating strong market performance with a trading volume of 198,644 shares.
• Analysts are optimistic about Indivior, with a consensus rating of “Buy” and some firms issuing price targets as high as $27.00.
• In its latest earnings report, Indivior reported $0.51 earnings per share, significantly exceeding expectations and showcasing a revenue of $302 million.

Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) hit a new 52-week high during trading on Wednesday . The company traded as high as $25.00 and last traded at $24.48, with a volume of 198644 shares. The stock had previously closed at $24.46.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Jefferies Financial Group began coverage on Indivior in a report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 price objective for the company. Craig Hallum restated a "buy" rating on shares of Indivior in a research note on Wednesday. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Finally, HC Wainwright began coverage on Indivior in a research note on Wednesday, August 6th. They set a "buy" rating and a $27.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $19.60.

Indivior Stock Down 0.2%

The business has a 50-day simple moving average of $18.22 and a 200-day simple moving average of $13.24. The company has a market cap of $3.36 billion, a PE ratio of 39.54 and a beta of 0.74.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.25. The business had revenue of $302.00 million during the quarter, compared to the consensus estimate of $239.43 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. On average, research analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Indivior in the 2nd quarter valued at about $26,000. GF Fund Management CO. LTD. bought a new stake in shares of Indivior during the fourth quarter worth about $36,000. Amalgamated Bank acquired a new stake in Indivior in the second quarter valued at $61,000. Lazard Asset Management LLC bought a new stake in shares of Indivior during the 4th quarter valued at about $57,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock valued at $71,000 after buying an additional 666 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.